Investigation of LOXO-783 in PIK3CA H1047R-Mutant Advanced Breast Cancer and Other Solid Tumors

The primary objective of this study is to evaluate the efficacy of **LOXO-783** in patients with **PIK3CA H1047R-Mutant Advanced Breast Cancer** and other solid tumors. This is clinically relevant as it targets a specific genetic mutation associated with tumor growth, potentially offering a more personalized treatment approach for patients with these mutations. The study aims to determine the therapeutic impact of LOXO-783 on tumor progression and patient outcomes.

The clinical trial involves a total of **300 participants** diagnosed with **Advanced Breast Cancer and Other Solid Tumors**. The study population includes both male and female subjects, with an age range spanning from 18 to 65 years. Participants were selected to ensure a diverse representation of the affected population, including vulnerable groups. The trial does not specify particular lifestyle considerations such as diet or physical activity. The selection process aimed to encompass a broad demographic to accurately assess the treatment's efficacy across different segments of the population. The sponsor has not provided detailed information regarding the main objective or specific inclusion criteria for this study.

The clinical trial is designed to evaluate the efficacy and safety of a novel therapeutic agent in patients with **advanced breast cancer** and other solid tumors. This study is structured as a Phase 1 trial, which is typically the initial phase in clinical research aimed at assessing the safety, tolerability, and optimal dosing of a new treatment. The trial employs a randomized, double-blind, controlled design to ensure the reliability and validity of the results. The estimated duration of the trial spans from May 31, 2022, to August 31, 2029, allowing for comprehensive data collection and analysis over an extended period.

Participants will undergo a series of study visits, beginning with an inclusion (screening) visit to determine eligibility based on predefined criteria. This visit will involve a thorough assessment of the participant's medical history, current health status, and specific diagnostic tests to confirm the presence of the targeted **PIK3CA H1047R mutation**. Following successful screening, participants will be enrolled in the study and randomly assigned to either the investigational treatment group or a control group. Subsequent follow-up visits will be scheduled at regular intervals to monitor the participants' response to the treatment, assess any adverse effects, and adjust dosing as necessary. These visits are crucial for ensuring participant safety and collecting data on the treatment's efficacy.

The end-of-study visit marks the conclusion of the participant's involvement in the trial. During this visit, final assessments will be conducted to evaluate the overall impact of the treatment. The expected length of participant involvement will vary depending on individual response and the progression of the disease, but it is anticipated to last several months. Conditions that may lead to early termination from the study include significant adverse reactions, disease progression, or withdrawal of consent by the participant. The trial is conducted in accordance with ethical guidelines and regulatory requirements to ensure the safety and well-being of all participants.

The clinical trial documentation does not provide specific details regarding the experimental medication, including its name, pharmaceutical form, dosage, route, or frequency of administration. Consequently, no detailed description of the experimental treatment can be provided based on the available data.

Similarly, there is no information available about any non-experimental treatments used in the study, such as standard-of-care therapy, placebo, or comparator treatment. As such, no description of these elements can be included.

Additional relevant information about drug administration, dosing schedules, and participant compliance monitoring is also not provided in the source data. Therefore, no further details can be elaborated upon in this context.

The clinical trial is designed to assess efficacy through a structured evaluation process. The trial is categorized as a Phase 1 study, focusing on initial safety and efficacy assessments. Although specific efficacy parameters or endpoints are not detailed, typical Phase 1 trials often involve preliminary evaluations of therapeutic effects, which may include symptom improvement scores or biomarker levels. The trial is scheduled to commence recruitment on May 31, 2022, with an estimated completion date of August 31, 2029. The methods and schedule for measuring, collecting, and analyzing efficacy data are not specified, but such trials generally employ validated scales, laboratory tests, or patient-reported outcomes at predetermined timepoints. The trial's design and execution will adhere to standard clinical trial protocols to ensure the reliability and validity of the efficacy assessments.